U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
AstraZeneca’s Evusheld is a long-acting combination of antibodies (tixagevimab and cilgavimab) approved by the U.S. Drug Administration (FDA) for emergency use to prevent COVID-19. The first shipments are expected to be available soon.
Related news
Are the drug and dietary supplement vending machines coming?
The soon-to-be widely available medicine vending machines, which are currently…
Read more >
Medicines, yes, but we don’t look for healing on the Internet
In the case of a health complaint they have not…
Read more >
BENU and Foglaljorvost.hu signed a cooperation agreement
Hungary’s best-known pharmacy network and the country’s largest healthcare appointment…
Read more >
More related news >
Related news
Müller Drogéria Hungary has recalled MadeGood Bio Granola muesli bars in various flavors
Due to the presence of metal filings, Müller Drogéria Magyarország…
Read more >
The world is celebrating the resurgence of retro gaming, and it’s time to get to know it a little better
The huge success of the TV series Stranger Things, which…
Read more >
GUVET high fashion clothing brand breaks into the global market with Hungarian goose feathers
On December 3rd, FBZ Hungária, the largest Hungarian down distributor,…
Read more >
){kind=link}